229 related articles for article (PubMed ID: 20962031)
21. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
[TBL] [Abstract][Full Text] [Related]
23. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway.
Wang WJ; Mao LF; Lai HL; Wang YW; Jiang ZB; Li W; Huang JM; Xie YJ; Xu C; Liu P; Li YM; Leung ELH; Yao XJ
Pharmacol Res; 2020 Nov; 161():105129. PubMed ID: 32783976
[TBL] [Abstract][Full Text] [Related]
24. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
Qiu M; Ke L; Zhang S; Zeng X; Fang Z; Liu J
Cancer Chemother Pharmacol; 2017 Aug; 80(2):275-286. PubMed ID: 28608259
[TBL] [Abstract][Full Text] [Related]
25. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
26. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
27. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
[TBL] [Abstract][Full Text] [Related]
28. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
29. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
[TBL] [Abstract][Full Text] [Related]
30. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V; Saavedra JE; Nieves-Alicea R; Simeone AM; Keefer LK; Tari AM
Int J Oncol; 2011 Apr; 38(4):963-71. PubMed ID: 21271218
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
[TBL] [Abstract][Full Text] [Related]
32. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
33. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
Kaczmarek MZ; Holland RJ; Lavanier SA; Troxler JA; Fesenkova VI; Hanson CA; Cmarik JL; Saavedra JE; Keefer LK; Ruscetti SK
Leuk Res; 2014 Mar; 38(3):377-82. PubMed ID: 24461365
[TBL] [Abstract][Full Text] [Related]
35. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Kiziltepe T; Hideshima T; Ishitsuka K; Ocio EM; Raje N; Catley L; Li CQ; Trudel LJ; Yasui H; Vallet S; Kutok JL; Chauhan D; Mitsiades CS; Saavedra JE; Wogan GN; Keefer LK; Shami PJ; Anderson KC
Blood; 2007 Jul; 110(2):709-18. PubMed ID: 17384201
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O
Kang F; Ai Y; Zhang Y; Huang Z
Eur J Med Chem; 2018 Apr; 149():269-280. PubMed ID: 29501947
[TBL] [Abstract][Full Text] [Related]
37. Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors.
Liu Y; Wang X; Li J; Tang J; Li B; Zhang Y; Gu N; Yang F
Adv Mater; 2021 Jul; 33(30):e2101701. PubMed ID: 34106489
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Guenzle J; Garrelfs NWC; Goeldner JM; Weyerbrock A
Mol Neurobiol; 2019 Sep; 56(9):6046-6055. PubMed ID: 30715649
[TBL] [Abstract][Full Text] [Related]
39. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
Liu L; Huang Z; Chen J; Wang J; Wang S
J Exp Clin Cancer Res; 2018 Jul; 37(1):142. PubMed ID: 29986744
[TBL] [Abstract][Full Text] [Related]
40. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo.
Wu SH; Bau DT; Hsiao YT; Lu KW; Hsia TC; Lien JC; Ko YC; Hsu WH; Yang ST; Huang YP; Chung JG
Environ Toxicol; 2017 Apr; 32(4):1305-1317. PubMed ID: 27444971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]